gretel
11 Dec 2015
Good news today A number of positives in today's RNS's: - Davy coming in as main broker and NOMAD. This is a big step up from Hybridan - a listing on the ESM, which will aid investor interest and liquidity - the CEO's comment that this is "at a time of strong growth and our move into profitability"[link]
gretel
23 Oct 2015
RNS - big contract win Another €1m+ contract win for VENN - these are big contracts for a mere £9m m/cap company, but in particular the fact that it's repeat business is very encouraging:[link] "Contract for over €1m with leading French BiotechVenn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of a project worth in excess of €1m with a leading French Biotech company. The Phase I-II project is centred on acute T-cell leukaemia ('ATL'), and will cover multiple regions, including France (and French administered overseas territories), the UK and the US. This project will run for 33 months and follows on from a previous successful trial with the same company. Tony Richardson, Chief Executive Officer of Venn said: "The €1m project illustrates the high standard of execution for Venn's projects and how this can be used to generate repeat customer business. We have a growing client base, a strong book of business and a clear opportunity to secure more repeat business through high performance.""
gretel
22 Sep 2015
Good news today Excellent stuff: - good H1 results and very confident outlook for a profitable H2 - acquisition at 23p and oversubscribed placing at 22p - Kinesis Pharma already makes historic €0.6m EBITDA so is nicely earnings enhancingNo reason why the share price shouldn't continue to advance from here imo.Brief analyst comment amongst other coverage:[link] Lynne at broker Hybridan said Venn was a good match with Kinesis.He added that half-yearly results were well on track to meet market expectations, with €9m in new contract wins."Combined with the accretive contribution from Kinesis, the future looks very promising," he said."
gretel
13 Aug 2015
Excellent trading update today A very confident trading update, with H1 revenues in excess of €4m, which puts VENN easily on track to meet - or beat - forecasts of €8m for the year:[link] Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces a strong first half of 2015 with the Company billing in excess of €4m, up 170% against the same period in 2014 (H1: €1.5m). The Company has demonstrated continued growth throughout 2015 driven by contract wins amounting to over €9m in the period to 30 June 2015. Commenting on the figures, Venn CEO, Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the Company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth." Venn will announce its interim results for the six months ended 30 June 2015 on the 22 September 2015."
gretel
29 Jul 2015
Techinvest say Buy The July issue of Techinvest is now available free on their web site, so here's what they had to say about VENN, which is one of their Best Buys for H2'15:[link] Life Sciences (VENN; 21p) was also a Nap Tip for 2015 (at 17p) in the January issue this year. Back then, we reckoned the shares were overdue a significant rerating. Gain to date: 23.5%.Last month’s issue (Page 2) contained a review of progressive results for the year to December 31 last. This also noted that house broker Zeus Capital was looking for revenue of €8.22m for 2015, with earnings per share at breakeven.On June 10, a €2m contract over four years was announced with a leading Europeanbiotech company (see Page 4 for further detail). This came on the back of €4.1m in new contracts reported in March with a US based biotech (see Page 4, May issue)."VENN was also featured a second time in the issue as a straight Buy tip at 21p:"Venn Life Sciences (VENN; AIM) # 21pVenn has secured a €2m contract with a European Biotech company to manage aPhase III study in the area of Rheumatology. The study will involve multiple European countries and will run over a four year period, with most activity occurring during year one.This deal brings the value of new CRO contracts signed so far this year to more than €6m. House broker Zeus Capital commented that, since the Phase III trials are usually the most complicated and extensive, this latest contract underscores the value of Venn’s service offering and geographic coverage.Zeus expects Venn to generate revenues of at least €8.2m for the current year to 31 December with a breakeven bottom line. This compares with €4.9m revenue last year.Venn is showing it is capable of winning complex, higher value contracts. Continue to buy."
